Ipamorelin: Dosing, Evidence & Protocol

01.The Selectivity Advantage

Ipamorelin is the first truly selective growth hormone secretagogue. It is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that binds the GHS-R1a (ghrelin) receptor on pituitary somatotrophs, triggering GH vesicle exocytosis through the Phospholipase C / IP3 / Ca2+ cascade.

What makes it selective: at doses up to 200 times above its GH-releasing ED50, Ipamorelin does not elevate ACTH, cortisol, or prolactin. This is its defining pharmacological feature and the reason it displaced GHRP-6 and GHRP-2 in clinical practice.

How It Differs from Earlier Secretagogues

GHRP-6: Comparable GH release but activates cortisol, prolactin, and appetite pathways. Causes significant hunger spikes.
GHRP-2: Slightly higher GH potency but measurable cortisol and prolactin elevation.
Ipamorelin: Equivalent GH output, zero hormonal side-channel activation, no appetite stimulation.

The selectivity is not just cleaner. It means fewer variables to manage: no cortisol-driven catabolism, no prolactin-related side effects, no ghrelin-mediated hunger interfering with body composition protocols.

02.The CJC-1295 Synergy Stack

Ipamorelin is most commonly administered alongside CJC-1295 (Modified GRF 1-29) because the two peptides activate complementary arms of the GH release system. CJC-1295 is a GHRH analog that stimulates GH transcription and secretion. Ipamorelin is a ghrelin mimetic that suppresses somatostatin and triggers GH vesicle release.

Dual-Pathway Mechanism

CJC-1295: GHRH receptor agonist. Presses the accelerator on GH production.
Ipamorelin: GHS-R1a agonist. Removes the somatostatin brake and triggers pulse release.
Combined: Stronger GH pulse amplitude than either alone, with cleaner offset than GHRP-based stacks.

The stack uses CJC-1295 without DAC (Modified GRF 1-29, ~30 minute half-life) to preserve natural pulsatile GH rhythms. The DAC version extends the CJC-1295 half-life to 6-8 days but risks continuous GH stimulation and receptor downregulation.

Ipamorelin's benefits are mediated through elevated GH and downstream IGF-1. The magnitude is smaller than pharmacological GH dosing but operates within physiological feedback loops.

Body Composition

Fat loss: GH activates hormone-sensitive lipase (HSL) for lipolysis. Visceral fat preferentially affected. Observational data shows meaningful reduction, but only when combined with caloric deficit.
Lean mass: IGF-1 drives protein synthesis through the PI3K-Akt-mTOR pathway. Conditional on resistance training and adequate protein intake (1.6-2.2 g/kg).

Skeletal and Connective Tissue

Bone density: Animal studies show increased bone mineral content through expanded cross-sectional area (matrix growth), not density alone. GH replacement RCTs confirm +7% lumbar spine BMD at 10-year follow-up.
Collagen synthesis: Up to 5.8-fold increase in tendon and skeletal muscle collagen, accelerating connective tissue repair.

Sleep Architecture

GH is secreted in high-amplitude pulses during stages 3 and 4 of non-REM sleep. Ipamorelin administered at bedtime amplifies this natural rhythm. Improved sleep quality is consistently the first reported benefit, typically within weeks 1-2.

Additional Effects

Skin elasticity: GH/IGF-1 stimulates dermal fibroblast proliferation and procollagen synthesis. Measurable changes at 2-3 months.
Insulin secretion: Direct stimulation of pancreatic beta cells via calcium channel pathways (distinct from GH-mediated effects, demonstrated in animal studies).
Immune modulation: GH receptors on lymphocytes support thymic function and T-cell maturation.

No FDA-approved dosing exists. Protocols are synthesised from the saturation dose research, clinic practice, and pharmacokinetic data.

Tier 1: Conservative Start

Dose: 1 mcg/kg body weight (e.g. 100 mcg for 100 kg) or flat 200-300 mcg
Frequency: Once daily at bedtime, fasted (2+ hours after last meal)
Schedule: 5 days on / 2 days off, or continuous daily
Duration: 12-16 weeks, then 4-8 week washout

Tier 2: Synergy Stack

Ipamorelin: 100-300 mcg subcutaneous
CJC-1295 (no DAC): 100 mcg subcutaneous, co-administered
Frequency: Bedtime (conservative) or twice daily (AM fasted + bedtime)
Duration: Same 12-16 week cycle with washout

Critical Rules

Fasting window: 2+ hours without food before injection. Insulin suppresses GH release at the pituitary.
Bedtime timing: Aligns with natural nocturnal GH secretory peak during slow-wave sleep.
Cycling: Mandatory washout prevents pituitary receptor downregulation. Skipping the break risks diminishing returns.
SC only: Ipamorelin carries a specific risk of death if administered intravenously. Subcutaneous injection is the only safe route.
WADA: Ipamorelin is prohibited under Section S2 of the WADA Prohibited List. Competitive athletes face disqualification.

Frequently Asked Questions

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide that selectively stimulates growth hormone release by binding the GHS-R1a (ghrelin) receptor on the pituitary gland. It is the first GH secretagogue that does not elevate cortisol, ACTH, or prolactin.

How is Ipamorelin different from GHRP-6?

Both release comparable amounts of growth hormone, but GHRP-6 also activates cortisol, prolactin, and appetite pathways. Ipamorelin is selective for GH only, producing no hunger spikes and no hormonal side-channel effects even at very high doses.

Does Ipamorelin increase appetite?

This is contested. Despite being a ghrelin mimetic, Ipamorelin's high selectivity means it does not significantly raise ghrelin-mediated hunger in most users. Some clinics report mild appetite increase, but it is far less pronounced than GHRP-6.

What is the standard Ipamorelin dose?

Research protocols use 1 mcg/kg body weight or a flat 200-300 mcg dose, administered subcutaneously at bedtime in a fasted state. This matches the saturation dose identified in pharmacological studies for maximal GH release.

Why is Ipamorelin combined with CJC-1295?

CJC-1295 (a GHRH analog) stimulates GH production while Ipamorelin suppresses somatostatin and triggers GH vesicle release. The dual pathway produces a stronger, cleaner GH pulse than either peptide alone.

How long does Ipamorelin take to work?

Sleep quality improvements are typically the first effect, noticed within 1-2 weeks. Skin and energy changes appear around month 2. Measurable body composition changes require 3-6 months of consistent use with appropriate training and nutrition.

Is Ipamorelin safe long term?

No multi-year human safety data exists. Short-term studies (up to 16 weeks) show a favourable profile, but long-term carcinogenicity, cardiovascular impact, and permanent pituitary changes remain unquantified. Cycling with washout periods is standard practice.

Can Ipamorelin be injected intravenously?

No. Clinical literature identifies a specific risk of death from IV administration due to immediate systemic reactions. Ipamorelin must only be administered subcutaneously.

PEPTIDE: Ipamorelin

01.The Selectivity Advantage

How It Differs from Earlier Secretagogues

02.The CJC-1295 Synergy Stack

Dual-Pathway Mechanism

Explore This Protocol

Safety Triggers

Research Gaps

Contrarian Views

Protocol Reference

Stay Ahead of the Research

03.Systemic Outcomes